Skip to content

Study · Randomized controlled trial · n = 124 · 2022

4 results

Doppler Imaging Assessment of Changes of Blood Flow in Adenomyosis After Higher-Dose Oxytocin: A Randomized Controlled Trial.

Li J, Chen J, Wang Y, Hu L, Zhang R, Chen W

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine10 Jan 2022Cited by 4 (Europe PMC)

PMID35005793 (opens in a new tab)DOI10.1002/jum.15923 (opens in a new tab)PepBankPUB-35005793
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In patients with adenomyosis, no severe adverse reactions occurred and vital signs were stable during oxytocin infusion at 0.06 to 0.36 U/min.

    In plain wordsIn women with adenomyosis, intravenous oxytocin caused no severe adverse reactions and vital signs stayed stable.

    Peptide
    Oxytocin
    Outcome
    No significant changeSevere adverse reactions and vital signs
    Study

    n = 124

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.06-0.36 U/min · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    During the trial, no severe adverse reactions occurred and the vital signs of all the patients were stable.
    1 context sentence
    Summary · context
    A total of 124 patients with AM were randomly divided into 4 groups with continuous intravenous infusion of OT as 0.06, 0.12, 0.24 and 0.36 U/min, respectively.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with adenomyosis, the change in lesion blood flow volume with oxytocin 0.06 U/min differed significantly from the three higher dose groups.

    In plain wordsIn women with adenomyosis, the change in lesion blood flow with the lowest oxytocin dose differed from the three higher doses.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedChange in blood flow volume of adenomyosis lesion artery, 0.06 U/min versus higher doses
    Study

    n = 124

    Comparator
    Other oxytocin doses
    Outcome group
    Vascular function · Reproductive and sexual health
    Studied dose
    0.06 U/min · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    Among the 4 groups, it was found that there was a significant difference in the change of blood flow volume of blood artery in AM lesions between 0.06 U/min OT group and the other three groups after intravenous drip of OT (P < .05)
    1 context sentence
    Summary · context
    A total of 124 patients with AM were randomly divided into 4 groups with continuous intravenous infusion of OT as 0.06, 0.12, 0.24 and 0.36 U/min, respectively.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with adenomyosis, blood flow volume change did not differ significantly among the oxytocin 0.12, 0.24 and 0.36 U/min groups.

    In plain wordsIn women with adenomyosis, lesion blood flow changed similarly with the three higher oxytocin doses.

    Peptide
    Oxytocin
    Outcome
    No significant changeChange in blood flow volume among 0.12, 0.24 and 0.36 U/min groups
    Study

    n = 124

    Comparator
    Other oxytocin doses
    Outcome group
    Vascular function · Reproductive and sexual health
    Studied dose
    0.12-0.36 U/min · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    but there was no significant difference in blood flow volume among the three groups (P > .05)
    1 context sentence
    Summary · context
    A total of 124 patients with AM were randomly divided into 4 groups with continuous intravenous infusion of OT as 0.06, 0.12, 0.24 and 0.36 U/min, respectively.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with adenomyosis, the difference in adverse drug reactions between oxytocin doses was statistically significant (P < .05).

    In plain wordsIn women with adenomyosis, the rate of side effects of intravenous oxytocin differed between doses.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedAdverse drug reactions by oxytocin dose
    Study

    n = 124

    Comparator
    Lower oxytocin doses
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.06-0.36 U/min · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    and the difference of adverse drug reactions was statistically significant with the increase of OT dose (P < .05).
    1 context sentence
    Summary · context
    A total of 124 patients with AM were randomly divided into 4 groups with continuous intravenous infusion of OT as 0.06, 0.12, 0.24 and 0.36 U/min, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.